Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 6/20 | 1.00 |
| ▸ | SRD5A2 | P31213 | 6/20 | 1.00 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633452 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| Hydrochloric Acid SCHEMBL8793978 | 0.99 | SRD5A1 (0.98) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL8793523 | 0.97 | SRD5A1 (0.95) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| N-Phenylbenzamide SCHEMBL6762152 | 0.95 | SRD5A1 (0.91) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL9386762 | 0.95 | SRD5A1 (0.91) | SRD5A1SRD5A2CNR1CNR2 | |
| SCHEMBL8792770 | 0.95 | SRD5A1 (0.90) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL8793385 | 0.93 | SRD5A1 (0.88) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL9336300 | 0.93 | SRD5A1 (0.86) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL9337867 | 0.91 | SRD5A1 (0.84) | SRD5A1SRD5A2CNR1CNR2MAPT | |
| SCHEMBL8792545 | 0.91 | SRD5A1 (0.83) | SRD5A1SRD5A2CNR1CNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0458207-B1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-26 | — | — | EP | claimed |
| US-5212320-A | Enzyme inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-18 | — | — | US | claimed |
| EP-0458207-A2 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-27 | — | — | EP | claimed |
| JP-4244061-A | — | — | None | — | — | JP | disclosed |
| EP-3220942-B1 | COMPOSITIONS COMPRISING LOW DOSE DESMOPRESSIN IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | SERENITY PHARMACEUTICALS LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-10286033-B2 | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist | SERENITY PHARMACEUTICALS, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-9925232-B2 | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor | SERENITY PHARMACEUTICALS, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170319646-A1 | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | FIRST GENERATION CAPITAL INC. (CA) | 2017-11-09 | — | — | US | disclosed |
| EP-3220942-A1 | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | Serenity Pharmaceuticals LLC (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-3024473-A1 | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A 5-ALPHA REDUCTASE INHIBITOR | ALLERGAN, INC. (US) | 2016-06-01 | — | — | EP | disclosed |
| WO-2016081772-A1 | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | ALLERGAN, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2015013453-A1 | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A 5-ALPHA REDUCTASE INHIBITOR | ALLERGAN, INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| US-8278291-B1 | Treatment of wrinkles and strias with 4-hydroxyandrostenedione or a derivative thereof | CURADIS GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-20100184213-A1 | APOCRINE CELL LINE | CONOPCO, INC. D/B/A UNILEVER | 2010-07-22 | — | — | US | disclosed |
| US-20070148123-A1 | Substances and agents for positively influencing collagen | WIELAND HEINRICH | 2007-06-28 | — | — | US | disclosed |
| EP-0458207-B1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-26 | — | — | EP | disclosed |
| US-5312829-A | Testosterone 5alpha-reductase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-17 | — | — | US | disclosed |
| US-5212320-A | Enzyme inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-18 | — | — | US | disclosed |
| JP-H04244061-A | INDOLE DERIVATIVE | FUJISAWA PHARMACEUT CO LTD | 1992-09-01 | — | — | JP | disclosed |
| EP-0458207-A2 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |